We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Alliance to Develop New Modules for Live Cell Imaging

By Biotechdaily staff writers
Posted on 09 Jun 2006
A collaboration to develop innovative new fluorescence-detection modules for integration with the Cell-IQ live-cell culturing and analysis system of Chip-Man Technologies Ltd. More...
(Tampere, Finland) has been announced by the company and by ArcDia Ltd. (Turku, Finland).

The new modules will be a first in live-cell imaging, enabling simultaneous measurement and analysis of cell events using both phase contrast and living dyes within the same culture under incubation.

Juha Korpinen, CEO, Chip-Man Technologies, said, "This development will greatly enhance the capabilities of the Cell-IQ to enable even more detailed information to be extracted from living cells. Professors Erkki Soini, Juhani Soini, and colleagues are widely respected in the field of fluorescence detection. We are very fortunate to have such key expertise available within our local academic institutions.”

Cell-IQ represents a major breakthrough in cell analysis by enabling real time monitoring of all morphologic and physiologic changes in cell lines, primary cells, co-cultures and monolayer tissue models. The Cell-IQ software "learns” to recognize and record cellular change and to output these results as real-time moving images and simple multi-parameter graphics.

The addition of a fluorescence detection module will enable the Cell IQ to identify specific siRNA and cDNA transcripts. This will allow them to be closely monitored and the resulting morphologic changes recorded within the population. Thus the measurement of the true rate of cellular stimulation to specific drugs will be possible. In addition researchers can select out those fluorophores that minimally affect cells or have a synergistic or antagonistic effect on target drugs, enabling better optimization and control of cell based experimentation.



Related Links:
Chip-Man Technologies

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.